The treatment blocks an immune-system pathway involved in the inflammation that causes psoriasis, offering patients another targeted treatment option without the need for injections. Approval follows four Phase 3 clinical trials involving around 2,500 people, which demonstrated improvements in psoriasis symptoms compared with placebo after 16 weeks.
UK approves new once-daily pill for moderate-to-severe psoriasis
The UK's medicines regulator has approved Icotyde, a new once-daily tablet for adults and adolescents aged 12 and over with moderate-to-severe plaque psoriasis who meet the treatment criteria.